Items where authors include "Olivier, C."

Article

Smith, L. orcid.org/0000-0002-4280-6323, Hoang, J., Gillson, S. et al. (10 more authors) (2026) Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): Protocol for a Data-Linkage Study Integrating Randomised Clinical Trials with National Healthcare Systems Data. BMJ Open. ISSN 2044-6055 (In Press)

Mehta, D., Cicero, R., Chiecchio, L. et al. (10 more authors) (2025) Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study. eJHaem, 6 (3). e1015. ISSN 2688-6146

Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026

Cook, G., Ashcroft, A.J., Senior, E. et al. (17 more authors) (2024) Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 11 (11). e816-e829. ISSN 2352-3026

Jones, J.R., Cairns, D.A. orcid.org/0000-0002-2338-0179, Menzies, T. et al. (14 more authors) (2023) Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. eClinicalMedicine, 62. 102099. ISSN 2589-5370

Jenner, M.W., Pawlyn, C., Davies, F.E. et al. (15 more authors) (2023) The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology, 201 (2). pp. 267-279. ISSN 0007-1048

Conference abstract

Pawlyn, C., Royle, K.-L. orcid.org/0000-0003-0225-1199, Senior, E. et al. (20 more authors) (2025) Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT. [Conference abstract]

Dawkins, B., Gkountouras, G., Meads, D. et al. (21 more authors) (2024) Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial. [Conference abstract]

Cook, G., Pawlyn, C., Royle, K.-L. et al. (20 more authors) (2024) IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial. [Conference abstract]

Pawlyn, C., Davies, F.E., Cook, G. orcid.org/0000-0001-7196-7364 et al. (16 more authors) (2024) Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial. [Conference abstract]

Gooding, S., Royle, K.-L. orcid.org/0000-0003-0225-1199, Kazeroun, M. et al. (28 more authors) (2024) Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial. [Conference abstract]

Reed, M., Cairns, D.A. orcid.org/0000-0002-2338-0179, Pawlyn, C. et al. (13 more authors) (2023) The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial. [Conference abstract]

Seymour, F., Taylor, C., Gilson, S. et al. (10 more authors) (2023) Senescent Immune Signature in Frail and Vulnerable Newly Diagnosed Myeloma Patients: A Cohort Analysis from the UK-MRA Myeloma XIV Fitness Study. [Conference abstract]

Proceedings Paper

Cook, G., Ashcroft, A.J., Senior, E.R. et al. (16 more authors) (2023) Ixazomib-based consolidation and maintenance prolongs progression-free survival after salvage autologous stem cell transplantation (sASCT): Results from interim analysis of UK-MRA myeloma XII (ACCoRD). In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, California, USA. American Society of Hematology , p. 783.